Home >
Medicine Info >
Lamistar 30 Tablet
Loading interface...

Lamistar 30 Tablet

Manufactured byHETERO HEALTHCARE LTD
ContainsLamivudine (150 mg) + Stavudine (30 mg)
Description
Lamistar 30 Tablet is a combination medicine used to treat human immunodeficiency virus (HIV) infections in adult patients. This combination medicine is not a cure for HIV; it only prevents the virus from multiplying in your body. Monitoring of liver function and kidney function may be necessary while receiving this medicine based on the clinical condition.
QUICK LINKS:
Side effectsConcernsUsage

Side effects

Major & minor side effects for Lamistar 30 Tablet

  • Unsteadiness
  • Weakness in arms, hands, legs or feet
  • Decrease in blood cell count
  • Nausea and vomiting
  • Abdominal pain or stomach pain
  • Diarrhea
  • Difficulty in falling or staying asleep
  • Depression
  • Chills and fever
  • Headache
  • Loss of appetite
  • Stuffy nose
  • Sore throat
  • Skin Rash
  • Muscle pain and cramps

Uses of Lamistar 30 Tablet

What is it prescribed for?

  • HIV infection
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to lamivudine, stavudine, or any other inactive ingredients present along with the formulation.

Moderate to severe liver impairment

This medicine is not recommended for use in patients with a moderate to severe liver impairment due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
General warnings

Lactic acidosis

This medicine should be used with extreme caution due to the increased risk of Lactic acidosis. Report any unusual symptoms to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Pancreatitis

This medicine may rarely cause pancreatitis in some patients. Report any unusual symptoms to the doctor immediately. Therapy may need to be discontinued if the patient develops any signs or symptoms of pancreatitis.

Kidney Diseases

This medicine should be used with extreme caution in patients with a known history of kidney diseases due to the increased risk of severe adverse effects. Regular monitoring of kidney function tests, appropriate dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Liver diseases

This medicine should be used with extreme caution in patients with mild liver impairment due to the increased risk of worsening of the patient's condition. Liver function should be assessed before initiating the treatment. Close monitoring of liver function is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition. This medicine is not recommended for use in patients with a moderate to severe liver impairment.

Fat redistribution

This medicine may cause fat gain or fat loss from the body. This may result in peripheral wasting, facial wasting, breast enlargement, and Cushingoid appearance. Close monitoring of body weight and body fat distribution is necessary while receiving this medicine. Any changes in the body should be informed to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Immune reconstitution syndrome

This medicine should be used with caution due to the increased risk of Immune reconstitution syndrome. Report any unusual symptoms to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Methotrexate

Leflunomide

Didanosine

Lomitapide

Teriflunomide

Efavirenz

Mipomersen

Disease interactions

Renal Dysfunction

This medicine should be used with extreme caution in patients with kidney diseases due to the increased risk of serious adverse effects. Close monitoring of kidney function, appropriate dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

Pancreatitis

This medicine may cause pancreatitis in some patients. Report any unusual symptoms to the doctor immediately. Therapy may need to be discontinued if the patient develops any signs or symptoms of pancreatitis.

Skin Rash

This medicine should be used with extreme caution due to the increased risk of serious and life-threatening skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by a rash. Seek emergency medical treatment in case of any unusual reactions such as a rash or blisters. Replacement with a suitable alternative may be required based on the clinical condition of the patient.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take this medicine exactly as instructed by the doctor. Do not take in larger or smaller quantities than recommended. Ensure that proper hygiene measures are adopted. Complete the course of treatment to prevent the spread of the infection. Close monitoring of liver function and kidney function may be necessary while receiving this medicine based on the clinical condition.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by stopping the human immunodeficiency virus (HIV) from multiplying. This helps in reducing the chances of development of acquired immunodeficiency syndrome (AIDS) and other HIV-related illnesses.
Legal Status

Unknown

Unknown

Unknown

Unknown

Classification

Category

Antiviral combinations

Schedule

Schedule H

[Internet]. 2019 [cited 10 May 2019]. Available from:

https://ciplamed.com/content/lamivir-s-30-tablets

Lamivudine - DrugBank [Internet]. Drugbank.ca. 2019 [cited 10 May 2019]. Available from:

https://www.drugbank.ca/drugs/DB00709

Stavudine - DrugBank [Internet]. Drugbank.ca. 2019 [cited 10 May 2019]. Available from:

https://www.drugbank.ca/drugs/DB00649
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 10 Jul 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.